Herbert Hovenkamp, Dec 13, 2011
In Lundbeck the Eighth Circuit affirmed a district court’s decision approving a merger of the only two drugs authorized to treat a rare but serious heart condition in infants. When the acquisition occurred Lundbeck owned a patented drug called Indocin IV, which at the time was the only drug approved by the FDA to treat this condition. It then acquired the rights to NeoProfen, a drug that had been developed but was still awaiting FDA approval. The two drug
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.97.14.91
Please verify email or join us to access premium content!